STERIS (STE) Stock Forecast & Price Target

$242.54

+3.49 (+1.46%)

(As of 09/30/2024 ET)

STERIS - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
3

Buy
3

Based on 6 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 3 have given a hold rating, and 3 have given a buy rating for STE.

Consensus Price Target

$246.00
1.43% Upside

According to the 6 analysts' twelve-month price targets for STERIS, the average price target is $246.00. The highest price target for STE is $265.00, while the lowest price target for STE is $215.00. The average price target represents a forecasted upside of 1.43% from the current price of $242.54.

Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

STE Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$246.00	$243.60	$241.60	$239.60
Forecasted Upside	1.43% Upside	1.04% Upside	11.16% Upside	11.18% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Protect Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

STERIS Stock vs. The Competition

Type	STERIS	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	1.43% Upside	822.99% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent STE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/3/2024	KeyCorp 3 of 5 stars	Boost Target	Overweight ➝ Overweight	$255.00 ➝ $265.00	+9.11%
8/8/2024	Needham & Company LLC 2 of 5 stars	Reiterated Rating	Hold
8/7/2024	JMP Securities 2 of 5 stars	Reiterated Rating	Market Outperform ➝ Market Outperform	$265.00 ➝ $265.00	+13.48%
8/7/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$260.00 ➝ $260.00	+11.66%
5/10/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$220.00 ➝ $225.00	-0.44%
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$225.00 ➝ $215.00	+5.65%
Get the Latest News and Ratings for STE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:29 AM ET.

Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 21, 2024. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

Here are some ways that investors could benefit from investing in STERIS plc:

STERIS plc recently increased its quarterly dividend from $0.52 to $0.57 per share, indicating a positive change and a dividend yield of 0.93%. This can provide investors with a steady income stream.
Institutional investors, owning 94.69% of the stock, have shown confidence in STERIS plc, with various funds increasing their holdings in the company. This institutional backing can be a positive sign for individual investors.
Analysts have given STERIS plc a consensus rating of "Moderate Buy" with a price target of $246.00, suggesting potential for stock price appreciation based on market expectations.
Recent analyst reports have upgraded STERIS plc, with several analysts reiterating "buy" or "overweight" ratings, indicating a favorable outlook on the company's performance and growth prospects.
Despite a slight decrease in stock price by 0.7%, STERIS plc has a strong market cap of $24.20 billion, reflecting the company's stability and market presence.

STERIS
Bear Case

Investors should be bearish about investing in STERIS plc for these reasons:

The dividend payout ratio (DPR) of STERIS plc is currently at 59.69%, which may indicate a relatively high portion of earnings being distributed as dividends, potentially limiting reinvestment for growth or other purposes.

STE Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $246.00, with a high forecast of $265.00 and a low forecast of $215.00.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" STE shares.
: According to analysts, STERIS's stock has a predicted upside of 1.43% based on their 12-month stock forecasts.
: STERIS has been rated by research analysts at JMP Securities, KeyCorp, Needham & Company LLC, and Stephens in the past 90 days.
: Analysts like STERIS less than other "medical" companies. The consensus rating score for STERIS is 2.50 while the average consensus rating score for "medical" companies is 2.78. Learn more on how STE compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Does Elon Musk control the U.S. gov’t? (Ad)

Elon has been advising the government to reopen America’s nuclear facilities for years, and now, with the help of Biden’s ADVANCE act, these facilities are once again going back online just as he requested. One company is poised to benefit from America’s nuclear revival like no other. Elon Musk is one of the few people who knows this.

Watch this new documentary and you’ll discover what Elon knows,

This page (NYSE:STE) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners